Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) insider Matthew Link sold 4,889 shares of the stock in a transaction on Wednesday, July 2nd. The shares were sold at an average price of $4.10, for a total value of $20,044.90. Following the completion of the transaction, the insider owned 832,293 shares of the company's stock, valued at $3,412,401.30. This trade represents a 0.58% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Sight Sciences Stock Performance
Shares of SGHT stock traded down $0.09 during trading on Thursday, reaching $3.43. The company had a trading volume of 81,120 shares, compared to its average volume of 210,446. The firm's 50 day simple moving average is $3.73 and its two-hundred day simple moving average is $3.14. The company has a debt-to-equity ratio of 0.51, a current ratio of 10.47 and a quick ratio of 9.99. Sight Sciences, Inc. has a one year low of $2.03 and a one year high of $8.45. The company has a market capitalization of $177.32 million, a PE ratio of -3.50 and a beta of 2.47.
Sight Sciences (NASDAQ:SGHT - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.28) earnings per share for the quarter, beating analysts' consensus estimates of ($0.29) by $0.01. Sight Sciences had a negative return on equity of 54.62% and a negative net margin of 63.24%. The business had revenue of $17.51 million for the quarter, compared to the consensus estimate of $16.51 million. Sell-side analysts forecast that Sight Sciences, Inc. will post -0.99 earnings per share for the current year.
Analyst Ratings Changes
A number of equities analysts recently weighed in on SGHT shares. Lake Street Capital increased their price target on Sight Sciences from $2.50 to $3.00 and gave the company a "hold" rating in a research report on Friday, May 9th. Needham & Company LLC reiterated a "hold" rating on shares of Sight Sciences in a research report on Wednesday, April 9th. Wall Street Zen raised Sight Sciences from a "sell" rating to a "hold" rating in a research note on Saturday, June 28th. Piper Sandler reissued a "neutral" rating and issued a $4.00 price objective (up from $3.50) on shares of Sight Sciences in a research note on Wednesday, June 18th. Finally, Citigroup reissued a "neutral" rating and issued a $3.60 price objective (up from $3.20) on shares of Sight Sciences in a research note on Thursday, May 22nd. Six investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $4.10.
Get Our Latest Stock Report on SGHT
Institutional Inflows and Outflows
A number of institutional investors have recently made changes to their positions in SGHT. ProShare Advisors LLC bought a new position in shares of Sight Sciences in the 4th quarter valued at approximately $36,000. Dynamic Technology Lab Private Ltd acquired a new stake in Sight Sciences in the 4th quarter valued at approximately $40,000. WealthTrust Asset Management LLC acquired a new stake in Sight Sciences in the 4th quarter valued at approximately $48,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Sight Sciences in the 4th quarter valued at approximately $50,000. Finally, Wells Fargo & Company MN grew its holdings in Sight Sciences by 53.4% in the 4th quarter. Wells Fargo & Company MN now owns 16,600 shares of the company's stock valued at $60,000 after buying an additional 5,781 shares during the last quarter. 55.51% of the stock is owned by institutional investors.
About Sight Sciences
(
Get Free Report)
Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.
Featured Stories
Before you consider Sight Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sight Sciences wasn't on the list.
While Sight Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
